钠-葡萄糖协同转运蛋白2抑制剂对慢性心力衰竭患者血清脂联素脑钠肽同型半胱氨酸影响研究

Effects of sodium-glucose co-transporter 2 inhibitors on serum adiponectin,brain natriuretic peptide and homocysteine in patients with chronic heart failure

目的探讨钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)对慢性心力衰竭患者血清脂联素(APV)、脑钠肽(RNP)、同型半胱氨酸(HCY)的影响。方法随机将2021年1月至2022年12月我院收治的92例慢性心力衰竭患者分为2组,对照组46例行常规抗心力衰竭干预,研究组在此基础上联合SGLT-2抑制剂,对比2组患者治疗效果、心功能、炎症因子、血清脂联素、脑钠肽、同型半胱氨酸水平变化及不良反应发生情况。结果研究组治疗效果高于对照组(P<0.05);治疗后研究组左心室书中舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)低于对照组,左心室射血分数(LVEF)高于对照组(P<0.05);治疗后研究组炎症因子水平低于对照组(P<0.05);治疗后研究组APN高于对照组,BNP、HCY低于对照组(P<0.05),2组不良反应率差异无统计学意义(P>0.05)。结论SGLT2i可有效提升慢性心力衰竭患者的心功能指标,缓解机体炎症反应,改善患者心血管结局,安全性较高,应在临床治疗中广泛使用。

Objective To investigate the effects of sodium-glucose co-transporter 2 inhibitors(SGLT2i)on serum adiponectin,brain natriuretic peptide and homocysteine in patients with chronic heart failure.Methods Ninety-two patients with chronic heart failure admitted to our hospital from January 2021to December 2022 were divided into two groups with a random number table method,and 46 patients in the control group underwent conventional anti-heart failure intervention,and 46 patients in the study group were treated with conventional anti-heart failure intervention combined with SGLT2i.The treatment effect,cardiac function,inflammatory factors,serum adiponectin,brain natriuretic peptide,homocysteine levels and adverse reactions of the two groups were compared.Results The treatment effect of the study group was higher than that of the control group(P<0.05).The left ventricular end-diastolic dimension(LVEDD),left ventricular end-diastolic dimension(LVESD)and left ventricular ejection fraction(LVEF)in the post-treatment study group were lower than those in the control group(P<0.05).The levels of inflammatory factors in the post-treatment study group were lower than those in the control group(P<0.05).The adiponectin(APN)in the post-treatment study group was higher than that in the control group,and brain natriuretic peptide(BNP)and homocysteine(HCY)were lower than those in the control group(P<0.05),and the adverse reaction rates between the two groups were not significantly different(P>0.05).Conclusion SGLT2i can effectively improve cardiac function indexes,relieve inflammation and improve cardiovascular outcomes in patients with chronic heart failure,and has a high safety profile and should be widely used in clinical treatment.